Expression of the NF-κB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively

Journal of Pathology

Volumn 206, Issue 2, 2005, Pages 123-134

  Tracey, Lorraine ^a   Pérez Rosado, Alberto ^a   Artiga, Maria Jesús ^a   Camacho, Francisca I ^a   Rodríguez, Antonia ^a   Martínez, Nerea ^a   Ruiz Ballesteros, Elena ^b   Mollejo, Manuela ^b   Martinez, Beatriz ^a   Cuadros, Marta ^a   Garcia, Juan F ^a   Lawler, Mark ^c   Piris, Miguel Á ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

^c ST JAMES S HOSPITAL   (Ireland)

Author keywords

BCL2; BIRC5; cDNA microarray; NF B; Non Hodgkin's lymphoma; Survivin; Tissue microarray

Indexed keywords

DNA POLYMERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PROTEIN BCL 2; SURVIVIN; BIRC5 PROTEIN, HUMAN; LIGAND; MICROTUBULE ASSOCIATED PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR PROTEIN;

ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CLASSIFICATION; CARCINOGENESIS; CELL CYCLE; CELL LINE; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 18; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA REPAIR; FOLLICULAR LYMPHOMA; GENE ACTIVATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE TARGETING; GERMINAL CENTER; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; IN VITRO STUDY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MARKER GENE; NONHODGKIN LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY; CLINICAL TRIAL; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; LYMPHOCYTOMA; METABOLISM; METHODOLOGY; MULTICENTER STUDY; PROTO ONCOGENE;

GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BCL-2; HUMANS; LIGANDS; LYMPHOMA, B-CELL; LYMPHOMA, NON-HODGKIN; LYMPHOMA, SMALL-CELL; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 19944405795     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1768     Document Type: Article

References (31)

1. Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood 2003;101:1220-1235.
2. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nature Immunol 2002;3:221-227.
3. Karin M, Cao Y, Greten FR, et al. NF-kappaB in cancer: from innocent bystander to major culprit. Nature Rev Cancer 2002; 2:301-310.
4. Shaffer AL, Rosenwald A, Hurt EM, et al. Signatures of the immune response. Immunity 2001;15:375-385.
5. Liston P, Fong WG, Korneluk RG. The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 2003; 22:8568-8580.
6. Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 2003; 114: 181-190.
7. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997;388:190-195.
8. Li JH, Kirkiles-Smith NC, McNiff JM, et al. TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells. J Immunol 2003;171:1526-1533.
9. Ehrhardt H, Fulda S, Schmid I, et al. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB. Oncogene 2003; 22:3842-3852.
10. Davis RE, Brown KD, Siebenlist U, et al. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194:1861-1874.
11. Tracey L, Villuendas R, Dotor AM, et al. Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. Blood 2003; 102:1042-1050.
12. Martinez N, Camacho FI, Algara P, et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Res 2003;63:8226-8232.
13. Pham LV, Tamayo AT, Yoshimura LC, et al. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171:88-95.
14. Rodriguez A, Martinez N, Camacho FI, et al. Variability in the degree of expression of phosphorylated IkBa in CLL cases with nodal involvement. Clin Cancer Res 2004;10:6796-6806.
15. Tracey L, Villuendas R, Ortiz P, et al. Identification of genes involved in resistance to interferon-alpha in cutaneous T-cell lymphoma. Am J Pathol 2002;161:1825-1837.
16. Martinez-Delgado B, Melendez B, Cuadros M, et al. Expression profiling of T-cell lymphomas differentiates peripheral and lymphoblastic lymphomas and defines survival related genes. Clin Cancer Res 2004;10:4971-4982.
17. Tracey L, Spiteri I, Ortiz P, et al. Transcriptional response of T cells to IFN-alpha: changes induced in IFN-alpha-sensitive and resistant cutaneous T cell lymphoma. J Interferon Cytokine Res 2004;24:185-195.
18. Ruiz-Ballesteros E, Mollejo M, Rodriguez A, et al. Splenic marginal zone lymphoma. Proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood 2005;(in press).
19. Sanchez-Beato M, Sanchez E, Garcia JF, et al. Abnormal PcG protein expression in Hodgkin's lymphoma. Relation with E2F6 and NFkappaB transcription factors. J Pathol 2004;204:528-537.
20. Bullido MJ, Artiga MJ, Recuero M, et al. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nature Genet 1998;18:69-71.
21. Liu L, Eby MT, Rathore N, et al. The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the Ikappa B kinase complex. J Biol Chem 2002;277:13 745-13 751.
22. Lam LT, Davis RE, Pierce J, et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005;11:28-40.
23. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275-282.
24. Pierce JW, Schoenleber R, Jesmok G, et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 1997;272:21 096-21 103.
25. Shishodia S, Aggarwal BB. Guggulsterone inhibits NF-kB and IkBa kinase activation, suppresses expression of antiapoptotic gene products and enhances apoptosis. J Biol Chem 2004 279:47 148-47 158.
26. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003;101:1535-1542.
27. Vega MI, Huerta-Yepaz S, Garban H, et al. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene 2004;23:3530-3540.
28. Reed JC, Bischoff JR. BIRinging chromosomes through cell division - and survivin' the experience. Cell 2000; 102:545-548.
29. Altieri DC. Validating survivin as a cancer therapeutic target. Nature Rev Cancer 2003;3:46-54.
30. Do RK, Hatada E, Lee H, et al. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000;192:953-964.
31. Zheng Y, Vig M, Lyons J, et al. Combined deficiency of p50 and cRel in CD4+ T cells reveals an essential requirement for nuclear factor kappaB in regulating mature T cell survival and in vivo function. J Exp Med 2003;197:861-874.